Celladon Corp (CLDN) 10.30 $CLDN
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
LifeSci Advisors Initiates Coverage of Celladon Corporation
Marketwire - Wed May 07, 5:02AM CDT
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Celladon Corporation (NASDAQ: CLDN), a clinical-stage company evaluating gene therapy and small molecule approaches to treat heart failure, a condition where the pumping of the heart can no longer keep up with systemic demand. Celladon's lead development candidate, MYDICAR, is an adeno-associated virus-mediated gene therapy that delivers a copy of the SERCA2a gene. The Company is currently testing MYDICAR in a randomized, placebo-controlled Phase IIb study that enrolled 250 heart failure patients. Data from the trial is expected in April 2015 and has the potential to support a marketing application in Europe. The FDA has granted Breakthrough Therapy Designation to MYDICAR, which could significantly accelerate the time to a potential U.S. approval decision.
Celladon to Report First Quarter 2014 Results on May 13, 2014
GlobeNewswire - Tue May 06, 5:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that it will report its results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific on Tuesday, May 13, 2014.
Celadon Presented 2013 Tier 1 Core Carrier Award by Alcoa
PR Newswire - Mon May 05, 8:12AM CDT
Celadon Group, Inc.'s (NYSE: CGI) Celadon Trucking Services announced recently that Alcoa, a global leader in lightweight metals engineering and manufacturing, recently recognized Celadon with its esteemed Tier 1 Core Carrier Award for 2013. Celadon was one of four trucking firms to be conferred the Tier 1 designation.
Celadon Group Reports March Quarter Results And Declares Dividend
PR Newswire - Tue Apr 29, 3:57PM CDT
Celadon Group Inc. (NYSE: CGI) today reported its financial and operating results for the three months ended March 31, 2014, the third fiscal quarter of the Company's fiscal year ending June 30, 2014.
Celladon to Host Investor and Analyst Day and Webcast on May 6th in New York City
GlobeNewswire - Tue Apr 29, 6:02AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it will host an Investor and Analyst Day on Tuesday, May 6, 2014 at 8:00 a.m. in New York City. Members of Celladon's senior management team will provide a business update and an overview of the Company's strategies to drive long-term growth and will offer perspective on the recent Breakthrough Therapy Designation granted to its lead product candidate MYDICAR - the first gene therapy based product candidate to receive this designation from the Food and Drug Administration (FDA).
Celadon Trucking Selected As Top Workplace in Indianapolis
PR Newswire - Mon Apr 21, 8:12AM CDT
Celadon Group, Inc. (NYSE:CGI) today announced that it has been named to "The Indianapolis Star Top Workplaces" list of the best places to work in Central Indiana for 2014. Well over 100 companies participated in the program and Celadon earned the 15th position in the large business category for the Top Workplaces Award.
Celadon Trucking Awarded 2013 Gold Carrier of the Year by Lowe's
PR Newswire - Wed Apr 16, 1:35PM CDT
Celadon Group, Inc.'s (NYSE: CGI) Celadon Trucking Services announced that it was recently recognized by home improvement retailer Lowe's Companies, Inc. with its prestigious Gold Carrier of the Year award. To achieve Gold status, carriers must exceed an overall 98% on-time performance, shipment status compliance and freight acceptance. In addition to carrier metrics, Lowe's also factors in outstanding customer service and value-added supply chain solutions provided by carriers. This is the second year in a row that Celadon has earned the esteemed Gold designation for consistently exceeding the transportation and logistics demands established by Lowe's.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 10, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Celladon Corp. Shares Are Pumped Up
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 10, 12:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celladon , a clinical-stage...
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and where preliminary clinical evidence suggests it provides a substantial improvement over existing therapies. Celladon is developing MYDICAR as a novel, first-in-class therapy for patients with chronic heart failure due to systolic dysfunction. MYDICAR uses genetic enzyme replacement therapy to correct the deficiency in the enzyme SERCA2a, which is an enzyme that becomes deficient in heart failure patients and results in inadequate pumping of the heart. Celladon has developed a companion diagnostic to identify the patients who are AAV1 NAb negative and therefore eligible for MYDICAR treatment.
Celadon Group, Inc. Announces Dates For Earnings Release And Conference Call
PR Newswire - Tue Apr 08, 9:58AM CDT
Celadon Group, Inc. (NYSE: CGI) will release its fiscal 2014 third quarter results on Tuesday, April 29 after the close of the market. A conference call to discuss the quarter will be held on Wednesday, April 30 at 11:00 a.m. Eastern Time.
Celadon Group, Inc. Announces The Sale Of Lease Portfolio Assets And Earnings Release Date
PR Newswire - Tue Apr 01, 11:39AM CDT
Celadon Group, Inc. (NYSE:CGI) ("Celadon"
announced today that it has agreed to sell its independent contractor lease portfolio and associated assets to Element Financial Corporation (TSX:EFN) ("Element" . The existing portfolio includes approximately 600 leases and tractors that are currently in service with independent contractors with Celadon and other partner carriers. The purchase price of the transaction is approximately $53 million, which the company expects to use the funds to pay down its bank line. As part of this transaction, the company has also entered into a Program Agreement with Element under which Element will provide financing for the renewal and expansion of the transportation assets operated by independent lessees under contract to Celadon.
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
LifeSci Advisors Initiates Coverage of Celladon Corporation
Marketwire - Wed May 07, 5:02AM CDT
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Celladon Corporation (NASDAQ: CLDN), a clinical-stage company evaluating gene therapy and small molecule approaches to treat heart failure, a condition where the pumping of the heart can no longer keep up with systemic demand. Celladon's lead development candidate, MYDICAR, is an adeno-associated virus-mediated gene therapy that delivers a copy of the SERCA2a gene. The Company is currently testing MYDICAR in a randomized, placebo-controlled Phase IIb study that enrolled 250 heart failure patients. Data from the trial is expected in April 2015 and has the potential to support a marketing application in Europe. The FDA has granted Breakthrough Therapy Designation to MYDICAR, which could significantly accelerate the time to a potential U.S. approval decision.
Celladon to Report First Quarter 2014 Results on May 13, 2014
GlobeNewswire - Tue May 06, 5:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that it will report its results for the first quarter ended March 31, 2014 on Tuesday, May 13, 2014. The company will also hold a live investor conference call and webcast at 4:30pm Eastern/1:30pm Pacific on Tuesday, May 13, 2014.
Celadon Presented 2013 Tier 1 Core Carrier Award by Alcoa
PR Newswire - Mon May 05, 8:12AM CDT
Celadon Group, Inc.'s (NYSE: CGI) Celadon Trucking Services announced recently that Alcoa, a global leader in lightweight metals engineering and manufacturing, recently recognized Celadon with its esteemed Tier 1 Core Carrier Award for 2013. Celadon was one of four trucking firms to be conferred the Tier 1 designation.
Celadon Group Reports March Quarter Results And Declares Dividend
PR Newswire - Tue Apr 29, 3:57PM CDT
Celadon Group Inc. (NYSE: CGI) today reported its financial and operating results for the three months ended March 31, 2014, the third fiscal quarter of the Company's fiscal year ending June 30, 2014.
Celladon to Host Investor and Analyst Day and Webcast on May 6th in New York City
GlobeNewswire - Tue Apr 29, 6:02AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it will host an Investor and Analyst Day on Tuesday, May 6, 2014 at 8:00 a.m. in New York City. Members of Celladon's senior management team will provide a business update and an overview of the Company's strategies to drive long-term growth and will offer perspective on the recent Breakthrough Therapy Designation granted to its lead product candidate MYDICAR - the first gene therapy based product candidate to receive this designation from the Food and Drug Administration (FDA).
Celadon Trucking Selected As Top Workplace in Indianapolis
PR Newswire - Mon Apr 21, 8:12AM CDT
Celadon Group, Inc. (NYSE:CGI) today announced that it has been named to "The Indianapolis Star Top Workplaces" list of the best places to work in Central Indiana for 2014. Well over 100 companies participated in the program and Celadon earned the 15th position in the large business category for the Top Workplaces Award.
Celadon Trucking Awarded 2013 Gold Carrier of the Year by Lowe's
PR Newswire - Wed Apr 16, 1:35PM CDT
Celadon Group, Inc.'s (NYSE: CGI) Celadon Trucking Services announced that it was recently recognized by home improvement retailer Lowe's Companies, Inc. with its prestigious Gold Carrier of the Year award. To achieve Gold status, carriers must exceed an overall 98% on-time performance, shipment status compliance and freight acceptance. In addition to carrier metrics, Lowe's also factors in outstanding customer service and value-added supply chain solutions provided by carriers. This is the second year in a row that Celadon has earned the esteemed Gold designation for consistently exceeding the transportation and logistics demands established by Lowe's.
Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
Celladon Corporation was a big mover last session, as its shares rose nearly 12% on the day.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 10, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Celladon Corp. Shares Are Pumped Up
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 10, 12:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Celladon , a clinical-stage...
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. This designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and where preliminary clinical evidence suggests it provides a substantial improvement over existing therapies. Celladon is developing MYDICAR as a novel, first-in-class therapy for patients with chronic heart failure due to systolic dysfunction. MYDICAR uses genetic enzyme replacement therapy to correct the deficiency in the enzyme SERCA2a, which is an enzyme that becomes deficient in heart failure patients and results in inadequate pumping of the heart. Celladon has developed a companion diagnostic to identify the patients who are AAV1 NAb negative and therefore eligible for MYDICAR treatment.
Celadon Group, Inc. Announces Dates For Earnings Release And Conference Call
PR Newswire - Tue Apr 08, 9:58AM CDT
Celadon Group, Inc. (NYSE: CGI) will release its fiscal 2014 third quarter results on Tuesday, April 29 after the close of the market. A conference call to discuss the quarter will be held on Wednesday, April 30 at 11:00 a.m. Eastern Time.
Celadon Group, Inc. Announces The Sale Of Lease Portfolio Assets And Earnings Release Date
PR Newswire - Tue Apr 01, 11:39AM CDT
Celadon Group, Inc. (NYSE:CGI) ("Celadon"
announced today that it has agreed to sell its independent contractor lease portfolio and associated assets to Element Financial Corporation (TSX:EFN) ("Element" . The existing portfolio includes approximately 600 leases and tractors that are currently in service with independent contractors with Celadon and other partner carriers. The purchase price of the transaction is approximately $53 million, which the company expects to use the funds to pay down its bank line. As part of this transaction, the company has also entered into a Program Agreement with Element under which Element will provide financing for the renewal and expansion of the transportation assets operated by independent lessees under contract to Celadon. 
